Trials / Terminated
TerminatedNCT00140894
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Rofecoxib in Familial Adenomatous Polyposis (FAP)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 62 (planned)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0966; rofecoxib / Duration of Treatment: 24 weeks | |
| DRUG | Comparator: placebo / Duration of Treatment: 24 weeks |
Timeline
- Start date
- 2002-08-06
- Completion
- 2004-10-11
- First posted
- 2005-09-01
- Last updated
- 2019-09-20
Source: ClinicalTrials.gov record NCT00140894. Inclusion in this directory is not an endorsement.